| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4370914 | Experimental Parasitology | 2016 | 6 Pages |
•Non-steroidal anti-inflammatory drug (NSAIDs), Diclofenac, targeting COX were tested against Acanthamoeba.•NSAIDs affected growth but not the viability of Acanthamoeba castellanii.•Importantly, NSAIDs abolished A. castellanii encystation.•Cyclooxygenases (COX-1 and COX-2) and prostaglandins play significant role(s) in Acanthamoeba biology.•NSAIDs in combination with other anti-amoebic drugs may help design improved preventative and/or therapeutic strategies.
Non-steroidal anti-inflammatory drug, Diclofenac, targeting COX have shown promise in the treatment of Acanthamoeba keratitis, but the underlying mechanisms remain unknown. Using various NSAIDs, Diclofenac sodium, Indomethacin, and Acetaminophen, here we determined the effects of NSAIDs on the biological properties of Acanthamoeba castellanii belonging to the T4 genotype. Using amoebicidal assays, the results revealed that Diclofenac sodium, and Indomethacin affected growth of A. castellanii. In contrast, none of the compounds tested had any effect on the viability of A. castellanii. Importantly, all NSAIDs tested abolished A. castellanii encystation. This is a significant finding as the ability of amoebae to transform into the dormant cyst form presents a significant challenge in the successful treatment of infection. The NSAIDs inhibit production of cyclo-oxegenase, which regulates the synthesis of prostaglandins suggesting that cyclooxygenases (COX-1 and COX-2) and prostaglandins play significant role(s) in Acanthamoeba biology. As NSAIDs are routinely used in the clinical practice, these findings may help design improved preventative strategies and/or of therapeutic value to improve prognosis, when used in combination with other anti-amoebic drugs.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
